Of more than 170 million doses delivered, about 134 million doses of Pfizer-BioNTech’s two-shot vaccine, which the FDA approved in December for emergency use in people ages 16 and up, have been administered in the U.S., according to the latest data from the Centers for Disease Control and Prevention.
“We are proud of the tremendous progress we’ve made since December in delivering vaccines to millions of Americans in collaboration with the U.S.
On March 31, the company said its vaccine has been 100% effective in a clinical trial of children ages 12 to 15, according to preliminary results.